Key Points
- Director Nilda Mesa sold 187 shares on December 9 at an average price of $481.63 for a total of $90,064.81, reducing her stake by 3.42% to 5,286 shares valued at about $2.55 million (SEC filing disclosed).
- Shares traded around $486.59 midday (12‑month range $266.98–$492.62) with a market cap of roughly $20.95 billion, a P/E of 18.44, and 50/200‑day moving averages of $456.09 and $371.91 respectively.
- Analysts are generally positive—MarketBeat shows a "Moderate Buy" consensus and $505 average target—and United Therapeutics recently beat quarterly EPS estimates ($7.16 vs. $6.89) despite revenue coming in slightly below expectations.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 187 shares of the firm's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $481.63, for a total transaction of $90,064.81. Following the completion of the sale, the director directly owned 5,286 shares of the company's stock, valued at approximately $2,545,896.18. This represents a 3.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
United Therapeutics Stock Performance
Shares of NASDAQ UTHR traded up $1.73 during midday trading on Thursday, hitting $486.59. 24,482 shares of the company traded hands, compared to its average volume of 577,229. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $492.62. The firm has a market cap of $20.95 billion, a P/E ratio of 18.44, a P/E/G ratio of 4.73 and a beta of 0.86. The stock has a 50-day moving average price of $456.09 and a 200 day moving average price of $371.91.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts' expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business's revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm posted $6.39 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms have commented on UTHR. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a report on Thursday, October 30th. UBS Group upped their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a "buy" rating in a research note on Thursday, November 6th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Oppenheimer increased their target price on United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Finally, Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $505.00.
Get Our Latest Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Large investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC bought a new position in shares of United Therapeutics in the second quarter worth approximately $29,000. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. SVB Wealth LLC purchased a new stake in shares of United Therapeutics during the 1st quarter valued at about $32,000. Finally, Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
